X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-08-18 | NTHI | Neonc Technologies Holdings, Inc. | Chen Thomas C | CEO, 10% | P - Purchase | $5.49 | +12,757 | 4,674,788 | 0% | +$69,998 | ||||||
| AM | 2026-04-10 | NTHI | Neonc Technologies Holdings, Inc. | Chen Thomas C | Chief Scientific Officer, 10% | P - Purchase | $4.09 | +47,207 | 4,671,083 | +1% | +$192,899 | |||||
2026-08-20 | PTIX | Protagenic Therapeutics, Inc.New | Armen Garo H | EXEC. CHAIR, PRINCIPAL OFF | P - Purchase | $0.59 | +16,634 | 53,533 | +45% | +$9,811 | ||||||
| D | 2026-08-19 | VRDN | Viridian Therapeutics, Inc.De | Tousignant Jennifer | GC | S - Sale+OE | $24.50 | -14,212 | 0 | -100% | -$348,194 | |||||
2026-08-18 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale | $71.98 | -186 | 9,570 | -2% | -$13,388 | ||||||
2026-08-18 | NKTR | Nektar Therapeutics | Robin Howard W | Pres, CEO | S - Sale | $71.98 | -418 | 54,655 | -1% | -$30,088 | ||||||
| M | 2026-08-19 | ETON | Eton Pharmaceuticals, Inc. | Brynjelsen Sean | Pres, CEO | S - Sale | $60.88 | -100,000 | 961,194 | -9% | -$6,087,773 | |||||
2026-08-19 | MGNX | Macrogenics Inc | Peters Jeffrey Stuart | SVP, GC,, Secretary | S - Sale | $4.15 | -31,105 | 0 | -100% | -$129,086 | ||||||
| M | 2026-08-18 | SKYE | Skye Bioscience, Inc. | Schwab Andrew J. | Dir, 10% | S - Sale | $0.37 | -375,840 | 9,305,923 | -4% | -$140,313 | |||||
| M | 2026-08-18 | SKYE | Skye Bioscience, Inc. | 5Am Partners Vii, LLC | 10% | S - Sale | $0.37 | -375,840 | 9,305,923 | -4% | -$140,313 | |||||
2026-08-18 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $3.38 | -631 | 673,853 | 0% | -$2,133 | ||||||
2026-08-18 | ARWR | Arrowhead Pharmaceuticals, Inc. | Olukotun Adeoye Y | Dir | S - Sale | $86.96 | -2,000 | 31,600 | -6% | -$173,920 | ||||||
2026-08-18 | RCKT | Rocket Pharmaceuticals, Inc. | Shah Gaurav | CEO | S - Sale | $3.38 | -2,293 | 1,462,832 | 0% | -$7,753 | ||||||
2026-08-18 | ARWR | Arrowhead Pharmaceuticals, Inc. | Perry Michael S | Dir | S - Sale | $87.30 | -11,600 | 111,459 | -9% | -$1,012,680 | ||||||
| D | 2026-08-19 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $526.96 | -9,500 | 668,728 | -1% | -$5,006,104 | |||||
2026-08-19 | BHC | Bausch Health Companies Inc. | Lenar Aimee J. | Pres, US Pharma | S - Sale | $7.03 | -36,827 | 334,853 | -10% | -$258,894 | ||||||
| M | 2026-08-18 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $82.86 | -44,980 | 5,067,460 | -1% | -$3,727,251 | |||||
2026-08-18 | CORT | Corcept Therapeutics Inc | Mahoney David L | Dir | S - Sale | $118.25 | -103,606 | 1,159,686 | -8% | -$12,251,411 | ||||||
2026-08-17 | MDGL | Madrigal Pharmaceuticals, Inc. | Kelley Shannon T | GC | S - Sale | $514.97 | -664 | 11,474 | -5% | -$341,940 | ||||||
2026-08-18 | ACRV | Acrivon Therapeutics, Inc. | Peterson Katharine | Chief Accounting Officer | S - Sale | $2.01 | -101 | 18,033 | -1% | -$203 | ||||||
2026-08-18 | KROS | Keros Therapeutics, Inc. | Tanini Annita | Corp. Controller, VP, Finance | S - Sale | $10.29 | -1,224 | 45,144 | -3% | -$12,595 | ||||||
2026-08-18 | KROS | Keros Therapeutics, Inc. | Lerner Lorena Raquel | Chief Scientific Officer | S - Sale | $10.29 | -3,568 | 27,559 | -11% | -$36,715 | ||||||
2026-08-18 | KROS | Keros Therapeutics, Inc. | Cho Esther | GC | S - Sale | $10.29 | -4,485 | 35,770 | -11% | -$46,151 | ||||||
2026-08-18 | KROS | Keros Therapeutics, Inc. | Newton Charles W. | Dir | S - Sale | $10.30 | -551 | 12,114 | -4% | -$5,675 | ||||||
2026-08-18 | ACRV | Acrivon Therapeutics, Inc. | Miller Mary | GC | S - Sale | $2.01 | -185 | 82,009 | 0% | -$372 | ||||||
2026-08-19 | RAPP | Rapport Therapeutics, Inc. | Yeleswaram Krishnaswamy | Chief Development Officer | S - Sale | $49.90 | -404 | 246,022 | 0% | -$20,160 | ||||||
2026-08-18 | ACRV | Acrivon Therapeutics, Inc. | Gamelin Erick | Chief Development Officer | S - Sale | $2.01 | -400 | 52,592 | -1% | -$804 | ||||||
2026-08-18 | ACRV | Acrivon Therapeutics, Inc. | Devroe Eric | COO | S - Sale | $2.01 | -604 | 146,349 | 0% | -$1,214 | ||||||
2026-08-18 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO | S - Sale | $2.01 | -1,713 | 2,629,947 | 0% | -$3,443 | ||||||
| D | 2026-08-19 | PVLA | Palvella Therapeutics, Inc. | Goin Kathleen | COO | S - Sale+OE | $152.21 | -4,302 | 0 | -100% | -$654,791 | |||||
2026-08-20 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.05 | +11,500 | 9,378,656 | 0% | +$518 | ||||||
2026-08-19 | PTIX | Protagenic Therapeutics, Inc.New | Armen Garo H | EXEC. CHAIR, PRINCIPAL OFF | P - Purchase | $0.35 | +2,700 | 36,899 | +8% | +$945 | ||||||
2026-08-19 | PHIO | Phio Pharmaceuticals Corp. | Plott Ronald Todd | Dir | P - Purchase | $1.14 | +15,000 | 15,000 | New | +$17,100 | ||||||
2026-08-19 | CAMP | Camp4 Therapeutics Corp | Tardiff Daniel | Chief Scientific Officer | S - Sale | $4.76 | -1,738 | 0 | -100% | -$8,273 | ||||||
| DM | 2026-08-17 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale+OE | $75.09 | -79,534 | 142,265 | -36% | -$5,972,206 | |||||
| D | 2026-08-18 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | SVP, GLOBAL CONTROLLER | S - Sale+OE | $100.00 | -40,000 | 1,274 | -97% | -$4,000,000 | |||||
2026-08-14 | ZNTL | Zentalis Pharmaceuticals, Inc. | Walters Group | 10% | P - Purchase | $3.50 | +4,335,000 | 17,844,973 | +32% | +$15,172,500 | ||||||
| D | 2026-08-19 | DNTH | Dianthus Therapeutics, Inc. /De/ | Read Simon | Dir | S - Sale+OE | $117.55 | -2,778 | 0 | -100% | -$326,554 | |||||
2026-08-17 | ANTX | An2 Therapeutics, Inc. | Readnour Robin Shane | Dir | S - Sale | $6.01 | -35,402 | 642,944 | -5% | -$212,702 | ||||||
| D | 2026-08-17 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $72.57 | -2,813 | 105,272 | -3% | -$204,127 | |||||
| D | 2026-08-17 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale+OE | $26.18 | -4,730 | 36,475 | -11% | -$123,835 | |||||
2026-08-17 | NATR | Natures Sunshine Products Inc | Prescott Group Capital Management, L.L.C. | 10% | P - Purchase | $14.69 | +20,000 | 1,944,486 | +1% | +$293,800 | ||||||
| D | 2026-08-18 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $515.60 | -9,500 | 668,728 | -1% | -$4,898,221 | |||||
2026-08-18 | RPRX | Royalty Pharma Plc | Hite Christopher | EVP, COB, Partnering | S - Sale | $59.97 | -100,000 | 393,601 | -20% | -$5,997,250 | ||||||
2026-08-17 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale | $58.58 | -6,018 | 40,036 | -13% | -$352,551 | ||||||
| D | 2026-08-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | CHIEF MEDICAL OFFICER | S - Sale+OE | $58.59 | -5,000 | 25,000 | -17% | -$292,931 | |||||
2026-08-18 | TAK | Takeda Pharmaceutical Co Ltd | Greenway Nicola Deidre Petal | CHRO | S - Sale | $18.11 | -12,980 | 40,049 | -24% | -$235,118 | ||||||
2026-08-17 | INSM | Insmed Inc | Sharoky Melvin Md | Dir | S - Sale | $127.53 | -5,000 | 267,901 | -2% | -$637,650 | ||||||
| DM | 2026-08-17 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | S - Sale+OE | $19.94 | -72,725 | 39,900 | -65% | -$1,450,419 | |||||
| D | 2026-08-17 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | S - Sale+OE | $20.00 | -1,000 | 51,776 | -2% | -$20,000 | |||||
2026-08-17 | KROS | Keros Therapeutics, Inc. | Bienaime Jean Jacques | Dir | P - Purchase | $10.27 | +1,000 | 19,592 | +5% | +$10,270 | ||||||
| DM | 2026-08-17 | TVTX | Travere Therapeutics, Inc. | Lyons Gary A | Dir | S - Sale+OE | $63.28 | -10,000 | 61,500 | -14% | -$632,846 | |||||
2026-08-18 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | COB, Pres, CEO | P - Purchase | $1.06 | +10,000 | 431,421 | +2% | +$10,600 | ||||||
2026-08-17 | TEVA | Teva Pharmaceutical Industries Ltd | Lippman Evan | EVP, Business Development | S - Sale | $36.57 | -18,600 | 25,591 | -42% | -$680,291 | ||||||
2026-08-19 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.06 | +10,000 | 9,365,456 | 0% | +$590 | ||||||
2026-08-14 | GRCE | Grace Therapeutics, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $2.09 | +11,608 | 2,760,000 | 0% | +$24,206 | ||||||
| D | 2026-08-17 | MANE | Veradermics, Inc | Durso Timothy August | Chief Technical Officer | S - Sale+OE | $107.82 | -43,500 | 78,142 | -36% | -$4,690,005 | |||||
| D | 2026-08-17 | MANE | Veradermics, Inc | Waldman Reid Alexander | CEO | S - Sale+OE | $107.86 | -67,500 | 170,824 | -28% | -$7,280,713 | |||||
2026-08-14 | ASND | Ascendis Pharma A/S | Bienaime Jean Jacques | Dir | P - Purchase | $246.33 | +2,000 | 2,900 | +222% | +$492,654 | ||||||
| DM | 2026-08-14 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO | S - Sale+OE | $36.34 | -664,826 | 18,630,739 | -3% | -$24,160,402 | |||||
| D | 2026-08-18 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale+OE | $32.03 | -4,767 | 25,655 | -16% | -$152,690 | |||||
| D | 2026-08-18 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. Md | Dir | S - Sale+OE | $32.03 | -12,567 | 124,557 | -9% | -$402,528 | |||||
| D | 2026-08-18 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | GC, Corp Sec | S - Sale+OE | $32.03 | -2,861 | 21,225 | -12% | -$91,639 | |||||
| D | 2026-08-17 | IRON | Disc Medicine, Inc. | Quisel John D | CEO | S - Sale+OE | $79.15 | -33,000 | 226,064 | -13% | -$2,611,982 | |||||
| D | 2026-08-14 | MLPT | Maplight Therapeutics, Inc. | Catalyst4, Inc. | 10% | P - Purchase | $11.38 | +4,400,000 | 25,306,689 | +21% | +$50,072,000 | |||||
| D | 2026-08-17 | JNJ | Johnson & Johnson | Taubert Jennifer L | EVP, WWC. Innovative Medicine | S - Sale+OE | $263.36 | -15,000 | 194,451 | -7% | -$3,950,400 | |||||
2026-08-14 | ADAG | Adagene Inc. | Do Cuong V | Dir | P - Purchase | $3.75 | +2,000 | 2,000 | New | +$7,500 | ||||||
2026-08-17 | ALXO | Alx Oncology Holdings Inc | Lettmann Jason | CEO | S - Sale | $1.93 | -2,230 | 294,379 | -1% | -$4,304 | ||||||
2026-08-17 | ALXO | Alx Oncology Holdings Inc | Wong Shelly | SVP, FINANCE, CAO | S - Sale | $1.93 | -573 | 87,828 | -1% | -$1,106 | ||||||
| D | 2026-08-17 | MCRB | Seres Therapeutics, Inc. | Brady Kelly | See Remarks | S - Sale+OE | $4.55 | -64 | 8,679 | -1% | -$291 | |||||
| D | 2026-08-17 | MCRB | Seres Therapeutics, Inc. | Shaff Eric D. | Dir | S - Sale+OE | $4.55 | -263 | 12,499 | -2% | -$1,197 | |||||
| D | 2026-08-17 | MCRB | Seres Therapeutics, Inc. | Henn Matthew R | See Remarks | S - Sale+OE | $4.55 | -81 | 7,995 | -1% | -$369 | |||||
| D | 2026-08-17 | MCRB | Seres Therapeutics, Inc. | Desrosier Thomas | See Remarks | S - Sale+OE | $4.55 | -82 | 8,117 | -1% | -$373 | |||||
2026-08-17 | PCRX | Pacira Biosciences, Inc. | Slonin Jonathan | Chief Medical Officer | S - Sale | $23.23 | -3,040 | 216,384 | -1% | -$70,619 | ||||||
| D | 2026-08-14 | ABBV | Abbvie Inc. | Donoghoe Nicholas | EVP, CHIEF BUS, STRAT OFFICER | S - Sale+OE | $250.00 | -32,710 | 74,430 | -31% | -$8,177,500 | |||||
2026-08-17 | VRCA | Verrica Pharmaceuticals Inc. | Zawitz David | COO | P - Purchase | $4.98 | +6,000 | 27,000 | +29% | +$29,880 | ||||||
| M | 2026-08-17 | VRCA | Verrica Pharmaceuticals Inc. | Rosenberg Noah L. | CMO | P - Purchase | $4.91 | +6,230 | 8,587 | +264% | +$30,610 | |||||
| M | 2026-08-14 | VRCA | Verrica Pharmaceuticals Inc. | Rieger Jayson | CEO, Pres | P - Purchase | $5.03 | +25,000 | 208,298 | +14% | +$125,750 | |||||
2026-08-18 | VRCA | Verrica Pharmaceuticals Inc. | Kirby John J. | Interim CFO | P - Purchase | $4.93 | +5,000 | 23,962 | +26% | +$24,650 | ||||||
| D | 2026-08-18 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $75.82 | -3,500 | 153,902 | -2% | -$265,370 | |||||
2026-08-18 | ELAN | Elanco Animal Health Inc | O'Neill Shiv | GC, CORP SEC | P - Purchase | $23.58 | +3,998 | 87,832 | +5% | +$94,273 | ||||||
| D | 2026-08-17 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $506.59 | -9,500 | 668,728 | -1% | -$4,812,568 | |||||
| D | 2026-08-14 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $114.49 | -3,664 | 119,472 | -3% | -$419,491 | |||||
2026-08-14 | CORT | Corcept Therapeutics Inc | Wilson James N | Dir | S - Sale | $111.43 | -10,000 | 1,474,543 | -1% | -$1,114,261 | ||||||
2026-08-17 | CORT | Corcept Therapeutics Inc | Robb Gary Charles | Chief Business Officer | S - Sale | $116.26 | -10,000 | 84,284 | -11% | -$1,162,572 | ||||||
| E | 2026-08-17 | LLY | Eli Lilly & Co | Jonsson Patrik | EVP, Pres, LLY Int'l | S - Sale | $0.18 | -6,500 | 54,779 | -11% | -$1,175 | |||||
| M | 2026-08-14 | NTHI | Neonc Technologies Holdings, Inc. | Chen Thomas C | CEO, 10% | P - Purchase | $3.86 | +36,259 | 4,660,135 | +1% | +$140,000 | |||||
2026-08-17 | AQST | Aquestive Therapeutics, Inc. | Barber Daniel | Pres, CEO | S - Sale | $4.29 | -25,000 | 585,574 | -4% | -$107,168 | ||||||
2026-08-18 | ABCL | Abcellera Biologics Inc. | Montalbano John S. | Dir | P - Purchase | $11.03 | +10,000 | 256,000 | +4% | +$110,300 | ||||||
2026-08-18 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | CEO, Pres, 10% | P - Purchase | $5.54 | +9,000 | 7,616,140 | 0% | +$49,860 | ||||||
2026-08-14 | PHVS | Pharvaris N.V. | Modig Berndt | CEO | S - Sale | $34.77 | -2,292 | 1,080,625 | 0% | -$79,686 | ||||||
2026-05-18 | CNSP | Cns Pharmaceuticals, Inc. | Fisher Michal | Dir | P - Purchase | $5.00 | +2,000 | 2,000 | New | +$10,000 | ||||||
| DM | 2026-04-23 | ENSC | Ensysce Biosciences, Inc. | Gower Bob G | Dir | P - Purchase | $0.49 | +908,614 | 916,740 | >999% | +$444,169 | |||||
| D | 2026-08-13 | OMER | Omeros Corp | Borges David J. | VP, Finance, CAO | S - Sale+OE | $16.95 | -5,000 | 0 | -100% | -$84,750 | |||||
2026-08-14 | APLM | Apollomics Inc. | Chen Yi-Kuei | COO | P - Purchase | $15.00 | +20,000 | 136,248 | +17% | +$300,000 | ||||||
2026-08-14 | APLM | Apollomics Inc. | Lin Peter Kuan-How | CFO | P - Purchase | $15.00 | +26,667 | 48,979 | +120% | +$400,005 | ||||||
2026-08-14 | APLM | Apollomics Inc. | Chen Hung-Wen | CEO | P - Purchase | $14.07 | +536,667 | 1,448,029 | +59% | +$7,550,004 | ||||||
2026-08-17 | ALKS | Alkermes Plc. | Nichols Christian Todd | SVP, Chief Commercial Officer | S - Sale | $49.23 | -7,576 | 102,193 | -7% | -$372,937 | ||||||
| M | 2026-08-14 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | CEO, Pres, 10% | P - Purchase | $3.91 | +15,000 | 7,607,140 | 0% | +$58,580 | |||||
| D | 2026-08-13 | CUE | Cue Biopharma, Inc. | Ray Sumita | Chief Legal Compliance Officer | S - Sale+OE | $30.09 | -8,829 | 118,545 | -7% | -$265,628 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |